{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:42:34Z","timestamp":1789400554918,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL101972"],"award-info":[{"award-number":["R01HL101972"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["13POST13730003"],"award-info":[{"award-number":["13POST13730003"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["13EIA12630000"],"award-info":[{"award-number":["13EIA12630000"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007804","name":"Oregon Clinical and Translational Research Institute","doi-asserted-by":"crossref","award":["UL1TR000128"],"award-info":[{"award-number":["UL1TR000128"]}],"id":[{"id":"10.13039\/100007804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.thromres.2014.11.009","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T05:46:29Z","timestamp":1416289589000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear"],"prefix":"10.1016","volume":"135","author":[{"given":"Cassandra P.","family":"Loren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Rigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie S.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen J.T.","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.11.009_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies","volume":"91","author":"Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.thromres.2014.11.009_bb0010","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.thromres.2014.11.009_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.thromres.2014.11.009_bb0020","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.thromres.2014.11.009_bb0025","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.thromres.2014.11.009_bb0030","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.thromres.2014.11.009_bb0035","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3324\/haematol.2012.064618","article-title":"Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy","volume":"97","author":"Neelakantan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.009_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0045","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thromres.2014.11.009_bb0050","first-page":"42","article-title":"Ponatinib pulled off market over safety issues","volume":"22","author":"Dalzell","year":"2013","journal-title":"Manag Care"},{"key":"10.1016\/j.thromres.2014.11.009_bb0055","first-page":"2014","article-title":"Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia","author":"Mathisen","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.thromres.2014.11.009_bb0060","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2011-02-331579","article-title":"S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation","volume":"118","author":"Aslan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-61779-307-3_7","article-title":"Platelet shape change and spreading","volume":"788","author":"Aslan","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.thromres.2014.11.009_bb0070","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1161\/ATVBAHA.112.301165","article-title":"p21 activated kinase signaling coordinates glycoprotein receptor VI-mediated platelet aggregation, lamellipodia formation, and aggregate stability under shear","volume":"33","author":"Aslan","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2014.11.009_bb0075","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/j.1538-7836.2005.01429.x","article-title":"GPVI and integrin alphaIIb beta3 signaling in platelets","volume":"3","author":"Watson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.009_bb0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.thromres.2014.11.009_bb0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1097-2765(00)80356-1","article-title":"Crystal structures of c-Src reveal features of its autoinhibitory mechanism","volume":"3","author":"Xu","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.thromres.2014.11.009_bb0090","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.11.009_bb0095","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1158\/0008-5472.CAN-12-1276","article-title":"The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL","volume":"72","author":"Hantschel","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.thromres.2014.11.009_bb0100","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"key":"10.1016\/j.thromres.2014.11.009_bb0105","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1538-7836.2012.04814.x","article-title":"Distinct and overlapping functional roles of Src family kinases in mouse platelets","volume":"10","author":"Severin","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.009_bb0110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1074-7613(00)80417-3","article-title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain","volume":"4","author":"Park","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.thromres.2014.11.009_bb0115","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1128\/MCB.19.12.8326","article-title":"LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI","volume":"19","author":"Pasquet","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.thromres.2014.11.009_bb0120","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/01.CIR.102.16.1931","article-title":"P-selectin expression on platelets determines size and stability of platelet aggregates","volume":"102","author":"Merten","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.11.009_bb0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0163-7827(03)00025-0","article-title":"Exposure of platelet membrane phosphatidylserine regulates blood coagulation","volume":"42","author":"Lentz","year":"2003","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.thromres.2014.11.009_bb0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","article-title":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","volume":"42","author":"Sadovnik","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.thromres.2014.11.009_bb0135","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","article-title":"The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0140","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1182\/blood-2010-12-326850","article-title":"Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation","volume":"117","author":"Mazharian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbrc.2013.05.022","article-title":"Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells","volume":"435","author":"Okabe","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.thromres.2014.11.009_bb0150","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1021\/bi301461t","article-title":"Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1","volume":"52","author":"Tourdot","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2014.11.009_bb0155","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood-2008-11-188516","article-title":"Lyn, PKC-delta, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion","volume":"114","author":"Chari","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0160","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1182\/blood-2010-09-304816","article-title":"Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation","volume":"117","author":"Ming","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0165","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2013-04-460147","article-title":"Biomarkers for prediction of venous thromboembolism in cancer","volume":"122","author":"Pabinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.009_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.critrevonc.2013.02.008","article-title":"Biomolecular markers of cancer-associated thromboembolism","volume":"88","author":"Hanna","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.thromres.2014.11.009_bb0175","doi-asserted-by":"crossref","first-page":"015014","DOI":"10.1088\/1478-3975\/8\/1\/015014","article-title":"Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells","volume":"8","author":"Berny-Lang","year":"2011","journal-title":"Phys Biol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T13:59:52Z","timestamp":1538056792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814006185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0049384814006185"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.009","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}